Agile Therapeutics, Inc.
AGRX
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -211.90% | 123.82% | -13.71% | 86.54% | 26.34% |
| Total Depreciation and Amortization | 7.37% | 10.75% | 9.89% | -62.60% | -83.98% |
| Total Amortization of Deferred Charges | -100.00% | -56.03% | -32.63% | -69.93% | -26.19% |
| Total Other Non-Cash Items | 891.20% | -225.48% | 161.53% | -48.70% | 81.31% |
| Change in Net Operating Assets | 165.91% | -102.79% | -35.47% | 139.84% | -150.92% |
| Cash from Operations | 102.74% | -55.24% | 111.03% | 102.19% | -190.35% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -718.22% | -116.89% | 97.14% | -- |
| Issuance of Common Stock | -100.00% | 336.29% | -99.89% | -99.68% | -41.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 225.84% | -173.79% | -102.83% | -43.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.17% | 107.22% | 64.85% | 101.28% | -117.71% |
